Becton, Dickinson and Co. (BDX) — Analysis Summary
Becton, Dickinson and Co. (BDX) has a market cap of $42.39B with year-over-year revenue growth of +8.2%. Net margin stands at 7.7%. The stock trades at a P/E ratio of 37.2.
Key Takeaways
- Revenue changed +8.2% year-over-year
- Net margin of 7.7%
- P/E ratio of 37.2
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, BDX posted revenue growth of +8.2% and trades at a P/E of 37.2.
Becton, Dickinson and Co. (BDX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.94x — current liabilities exceed current assets
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
72,000
Headquarters
FRANKLIN LAKES, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$4.20
Dividend Yield
2.79%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.